Therapeutic Response

BRAF p.V600E status confers therapeutic sensitivity to Pembrolizumab in patients with Melanoma.

Statements

Source and description
Keytruda (pembrolizumab) [product monograph]. HC. Health Canada approved pembrolizumab for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.